GE Healthcare and Novo Nordisk have joined forces to advance peripheral-focused ultrasound (PFUS) technology for treating chronic diseases like type 2 diabetes and obesity.
This collaboration aims to leverage their expertise in ultrasound medical technology and metabolic disease management to develop a PFUS solution that enhances patient care.
Early research indicates that PFUS has the potential to regulate metabolic function using ultrasound, with a focus on personalised ultrasound stimulation of nerve pathways to impact glucose metabolism in people with diabetes.
This innovative approach has the potential to offer alternative treatment options for the growing global diabetic population, which currently stands at an estimated 540 million adults, 90% of whom have type 2 diabetes.
Click here to read the original news story.